IP Library › Granted Patent US 12,258,355
Granted Patent B2
US 12,258,355 · App. 17/881,895 · Granted Mar 25, 2025

Probes for imaging huntingtin protein

Inventors: Celia Dominguez (Los Angeles, CA); Samuel Coe (Northampton, GB); Peter David Johnson (Oxfordshire, GB); Michael Edward Prime (Abingdon, GB); Christopher John Brown (Abingdon, GB); Sébastien René Gabriel Galan (Abingdon, GB); Paul Richard Giles (Abingdon, GB); Jonathan Bard (New York, NY); Elise Lucienne Paulette Gadouleau (Didcot, GB); Thomas Martin Krülle (Oxford, GB); Daniel Clark-Frew (Wantage, GB); John Wityak (Carlsbad, CA); Alex Kiselyov (New York, NY); Sarah Hayes (Oxfordshire, GB)
Assignee: CHDI Foundation, Inc.
C07D513/04A61B5/0035A61B6/032A61B6/037A61K51/0455A61K51/0459A61K51/0463C07D263/57C07D405/14C07D413/04C07D413/12C07D413/14C07D471/04C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,355
App. No.
17/881,895
Granted
Mar 25, 2025
Kind
B2
Abstract

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Claims (17)

1. A compound which is:

or a pharmaceutically acceptable salt thereof.

2. A compound which is:

or a pharmaceutically acceptable salt thereof,

wherein the compound, or a pharmaceutically acceptable salt thereof, is labeled with one or more positron-emitting radionuclides.

3. The compound of claim 2 , wherein said one or more positron-emitting radionuclides are selected from: 11 C, 13 N, 15 O, and 18 F.

4. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

5. A method of generating diagnostic images in an individual comprising administering an effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt thereof, to an individual, and generating an image of at least a part of said individual.

6. The method of claim 5 , wherein generating an image of at least a part of said individual comprises generating an image to detect a presence or absence of huntingtin protein (HTT protein) monomers or aggregates in a brain of said individual; and detecting a presence or absence of a pathologic process.

7. The method of claim 6 , wherein said HTT protein monomers or aggregates are present in the basal ganglia of said brain of said individual.

8. The method of claim 6 , wherein the pathologic process is a neurodegenerative disease.

9. The method of claim 8 , wherein the neurodegenerative disease is chosen from Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, Prion disease, and spinocerebellar ataxias.

10. The method of claim 9 , wherein the neurodegenerative disease is Huntington's disease (HD).

11. The method of claim 5 , wherein said effective amount of said compound comprises from about 0.1 to about 20 mCi.

12. The method of claim 11 , wherein said effective amount of said compound is about 10 mCi.

13. The method of claim 5 , wherein said generating an image comprises positron emission tomography (PET) imaging, PET with concurrent computed tomography imaging (PET/CT), PET with concurrent magnetic resonance imaging (PET/MRI), or a combination thereof.

14. The method of claim 13 , wherein said generating an image comprises PET imaging.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2024
From: DOMINGUEZ, CELIA; WITYAK, JOHN; BARD, JONATHAN; KISELYOV, ALEX
To: CHDI FOUNDATION, INC.
Reel/Frame 068650/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2024
From: BROWN, CHRISTOPHER JOHN; GALAN, SÉBASTIEN RENÉ GABRIEL; PRIME, MICHAEL EDWARD; GILES, PAUL RICHARD; GADOULEAU, ELISE LUCIENNE PAULETTE; KRÜLLE, THOMAS MARTIN; CLARK-FREW, DANIEL; JOHNSON, PETER DAVID; COE, SAMUEL; HAYES, SARAH
To: EVOTEC (UK) LTD.
Reel/Frame 068650/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2024
From: EVOTEC (UK) LTD.
To: CHDI FOUNDATION, INC.
Reel/Frame 068650/0605 →
Continuity (6)
Continuation 17558397 · Dec 21, 2021
Continuation 17325038 · May 19, 2021
Continuation 16530594 · Aug 2, 2019
Continuation 15507208
Provisional Application 62043603 · Aug 29, 2014
Related Publication 20230212190A1 · Jul 6, 2023
References Cited (79)
US 3985755A · Narayanan et al. · 1976 [cited by applicant]
US 4526976A · Fleck et al. · 1985 [cited by applicant]
US 5041453A · Huang et al. · 1991 [cited by applicant]
US 5661159A · Matsuo et al. · 1997 [cited by applicant]
US 5994378A · Matsuo et al. · 1999 [cited by applicant]
US 6770642B2 · Cole et al. · 2004 [cited by applicant]
US 8530483B2 · Barrow et al. · 2013 [cited by applicant]
US 10479802B2 · Dominguez · 2019 [cited by examiner]
US 11059836B2 · Dominguez · 2021 [cited by examiner]
US 11344637B2 · Dominguez et al. · 2022 [cited by applicant]
US 20060018825A1 · Kudo et al. · 2006 [cited by applicant]
US 20080267879A1 · Elmaleh et al. · 2008 [cited by applicant]
US 20080299041A1 · Jeong et al. · 2008 [cited by applicant]
US 20090123373A1 · Wang et al. · 2009 [cited by applicant]
US 20090163464A1 · Black et al. · 2009 [cited by applicant]
US 20100209345A1 · Katsifis et al. · 2010 [cited by applicant]
US 20110085985A1 · Barrow et al. · 2011 [cited by applicant]
US 20110160543A1 · Parsey et al. · 2011 [cited by applicant]
US 20110182812A1 · Szardenings et al. · 2011 [cited by applicant]
US 20120094996A1 · Fernandez et al. · 2012 [cited by applicant]
US 20120263646A1 · Catoen et al. · 2012 [cited by applicant]
US 20140193340A1 · Miller · 2014 [cited by applicant]
US 20170056535A1 · Dominguez et al. · 2017 [cited by applicant]
US 20170281804A1 · Dominguez et al. · 2017 [cited by applicant]
US 20170283436A1 · Dominguez et al. · 2017 [cited by applicant]
US 20170283439A1 · Dominguez et al. · 2017 [cited by applicant]
US 20170292150A1 · Dominguez et al. · 2017 [cited by applicant]
US 20190167821A1 · Dominguez et al. · 2019 [cited by applicant]
US 20210379211A1 · Dominguez et al. · 2021 [cited by applicant]
US 20210380608A1 · Dominguez et al. · 2021 [cited by applicant]
CN 102391260 · 2012 [cited by applicant]
DE 2909754 · 1980 [cited by applicant]
EP 0528337 · 1993 [cited by applicant]
EP 0729956 · 1996 [cited by applicant]
JP H02306916 · 1990 [cited by applicant]
JP H08325265 · 1996 [cited by applicant]
JP H11171886 · 1999 [cited by applicant]
JP 2011168515 · 2011 [cited by applicant]
WO WO199422846 · 1994 [cited by applicant]
WO WO1995006469 · 1995 [cited by applicant]
WO WO2002064576 · 2002 [cited by applicant]
WO WO2003048140 · 2003 [cited by applicant]
WO WO2004083195 · 2004 [cited by applicant]
WO WO2005040337 · 2005 [cited by applicant]
WO WO2010051196 · 2010 [cited by applicant]
WO WO2010112093 · 2010 [cited by applicant]
WO WO2011119565 · 2011 [cited by applicant]
WO WO2012074126 · 2012 [cited by applicant]
WO WO2013163244 · 2013 [cited by applicant]
WO WO2015008872 · 2015 [cited by applicant]
Auld et al., “A Basis for Reduced Chemical Library Inhibition of Firefly Luciferase Obtained from Directed Evolution,” Journal of Medicinal Chemistry, 2009, vol. 52, No. 5, pp. 1450-1458. [cited by applicant]
Beyer et al., “Zur 1,3-dipolaren Addition der Pyridinium-und Isochinolinium-betaine,” Journal für praktishe Chemie, 1966, pp. 293-303. [cited by applicant]
Cole et al., Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates, PNAS, 2010, vol. 107, No. 14, pp. 6222-6227. [cited by applicant]
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 293738-20-2, Entered STN: Oct. 9, 2000. [cited by applicant]
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 1367836-32-5, Entered STN: Apr. 13, 2012. [cited by applicant]
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 61382-21-6, Entered STN: Nov. 16, 1984. [cited by applicant]
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 349609-85-4, Entered STN: Aug. 1, 2001. [cited by applicant]
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 1122521-71-4, Entered STN: Mar. 17, 2009. [cited by applicant]
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 1485220-77-6, Entered STN: Dec. 13, 2013. [cited by applicant]
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 332042-92-9, Entered STN: Apr. 23, 2001. [cited by applicant]
Database Registry Chemical Abstracts Service, 2002, 2004, 2011, CAS registration Nos. 1349562-21-5, 1349042-30-3, 778543-33-2, 445218-48-4. [cited by applicant]
Dudkin, “Bioisosteric Equivalence of Five-Membered Heterocycles,” Chemistry of Heterocyclic Compounds, 2012, vol. 48, No. 1, pp. 27-32. [cited by applicant]
Extended European Search Report and Opinion dated Apr. 9, 2018 for EP Application No. 15836157.6, 15 pages. [cited by applicant]
Extended European Search Report and Opinion dated May 2, 2018 for EP Application No. 15836321.8, 11 pages. [cited by applicant]
Giordanetto et al., “Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening,” Bioorganic & Medical Chemistry Letters, 2011, vol. 21, pp. 829-835. [cited by applicant]
IHO, 1940, vol. 19, pp. 802-806. [cited by applicant]
International Preliminary Report on Patentability dated Feb. 28, 2017 for PCT/US2015/047427, 6 pages. [cited by applicant]
International Preliminary Report on Patentability dated Mar. 7, 2017 for PCT/US2015/047407, 6 pages. [cited by applicant]
International Search Report and Written Opinion dated Dec. 7, 2015 for PCT/US2015/047407, 8 pages. [cited by applicant]
International Search Report and Written Opinion dated Dec. 7, 2015 for PCT/US2015/047427, 13 pages. [cited by applicant]
Kinoshita et al., “A Short-Step Convenient Synthesis of 2-Phenylbenzofuran from 3-Phenylcoumarin,” Hererocycles, 2005, vol. 65, No. 7, pp. 1641-1654. [cited by applicant]
Mathis et al., “Synthesis and Evaluation of [cited by applicant]
Mukherjee et al., “Antispasmodic Compounds,” Journal of the Institution of Chemists, 1969, vol. 41, pp. 138-141. [cited by applicant]
Serdons et al., “Synthesis and Evaluation of Three [cited by applicant]
Song et al., “Molecular Chaperones and Protein Misfolding,” Liaoning Science and Technology Press, Mar. 2012, the 1st edition, pp. 6-10. [cited by applicant]
Song et al., “Synthesis and Evaluation of Anticonvulsant Activities of Triazole-Incorporated Benzothiazoles,” Letters in Drug Design & Discovery, 2014, vol. 11, pp. 488-494. [cited by applicant]
Supporting Information of Cole et al., “Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates,” PNAS, Apr. 6, 2010; vol. 107, No. 14, pp. 6222-6227. [cited by applicant]
Zeng et al., “Fluorine-18 Radiolabeled Heterocycles as PET Tracers for Imaging β-Amyloid Plaques in Alzheimer's Disease,” Current Topics in Medicinal Chemistry, 2013, 13(8), pp. 909-919. [cited by applicant]
Zhang et al., “ [cited by applicant]
Cited By (2)
US 12,606,570 US 12,661,415